MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Milestone Scientific EBITDA 2011-2026 | MLSS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Milestone Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.62 M | -6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 M | -8.76 M | -4.48 M |
Quarterly EBITDA Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 M | -4.2 M | -1.15 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
2.64 M | $ 28.36 | 0.46 % | $ 1.35 B |  USA |
 |
Haemonetics Corporation
HAE
|
337 M | $ 59.33 | 3.51 % | $ 2.99 B | USA |
 |
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | USA |
 |
Repro Med Systems
KRMD
|
-2.16 M | $ 4.33 | 2.85 % | $ 200 M | USA |
 |
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.39 | -7.73 % | $ 109 M |  Israel |
 |
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | USA |
 |
Alcon
ALC
|
580 M | $ 79.79 | 2.28 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 9.6 | 6.37 % | $ 23.3 M | USA |
 |
Envista Holdings Corporation
NVST
|
332 M | $ 26.83 | 1.67 % | $ 4.51 B | USA |
 |
Pro-Dex
PDEX
|
11.9 M | $ 52.0 | 1.01 % | $ 171 M | USA |
 |
The Cooper Companies
COO
|
1.06 B | $ 71.54 | 0.46 % | $ 14.2 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | USA |
 |
Retractable Technologies
RVP
|
-13.4 M | $ 0.7 | 3.72 % | $ 21 M | USA |
 |
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | USA |
 |
Harvard Bioscience
HBIO
|
-46.8 M | $ 4.71 | 9.28 % | $ 209 M | USA |
 |
electroCore
ECOR
|
-12.7 M | $ 6.33 | 4.03 % | $ 53.7 K | USA |
 |
Teleflex Incorporated
TFX
|
192 M | $ 122.58 | 3.53 % | $ 5.47 B | USA |
 |
Masimo Corporation
MASI
|
-164 M | $ 178.44 | 0.06 % | $ 9.51 B | USA |
 |
iRhythm Technologies
IRTC
|
-36.7 M | $ 119.48 | 3.68 % | $ 3.82 B | USA |
 |
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | USA |
 |
Merit Medical Systems
MMSI
|
308 M | $ 70.47 | 3.24 % | $ 4.17 B | USA |
 |
Glaukos Corporation
GKOS
|
-95 M | $ 118.91 | 2.16 % | $ 5.76 B | USA |
 |
ICU Medical
ICUI
|
244 M | $ 128.17 | 1.98 % | $ 3.16 B | USA |
 |
InfuSystem Holdings
INFU
|
15 M | $ 9.62 | 2.56 % | $ 199 M | USA |
 |
Utah Medical Products
UTMD
|
12.2 M | $ 66.5 | 0.91 % | $ 215 M | USA |
 |
STERIS plc
STE
|
1.34 B | $ 223.42 | 0.38 % | $ 22 B | USA |
 |
Intuitive Surgical
ISRG
|
3.55 B | $ 456.7 | 1.35 % | $ 163 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
LeMaitre Vascular
LMAT
|
78.3 M | $ 114.62 | - | $ 2.59 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-70 M | $ 11.98 | 2.26 % | $ 2.39 B | USA |
 |
BioLife Solutions
BLFS
|
-1.97 M | $ 20.07 | 1.67 % | $ 925 M | USA |
 |
Baxter International
BAX
|
673 M | $ 17.64 | 2.86 % | $ 9.05 B | USA |
 |
ResMed
RMD
|
1.16 B | $ 229.13 | 0.11 % | $ 33.5 B | USA |
 |
Pulse Biosciences
PLSE
|
-76.5 M | $ 19.11 | 2.36 % | $ 1.29 B | USA |
 |
Stereotaxis
STXS
|
-21.5 M | $ 1.94 | 3.74 % | $ 176 M | USA |
 |
STAAR Surgical Company
STAA
|
-83.4 M | $ 26.71 | 1.0 % | $ 1.32 B | USA |
 |
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
756 M | $ 256.95 | 0.17 % | $ 18.6 B | USA |
 |
AngioDynamics
ANGO
|
-14.2 M | $ 10.14 | 3.47 % | $ 414 M | USA |
 |
Becton, Dickinson and Company
BDX
|
5.04 B | $ 155.15 | 0.6 % | $ 44.6 B | USA |
 |
Nephros
NEPH
|
-1.38 M | $ 2.92 | -1.27 % | $ 30.3 M | USA |
 |
OraSure Technologies
OSUR
|
-61.8 M | $ 3.08 | 4.05 % | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
116 M | $ 121.94 | 1.53 % | $ 6.79 M | USA |